Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease

Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease

Abstract Purpose Autosomal recessive polycystic kidney disease (ARPKD) is a hereditary condition characterized by massive kidney enlargement and developmental liver defects. Potential consequences during childhood include the need for kidney replacement therapy (KRT). We report the design of 2 ongoi...

Full description

Bibliographic Details
Main Authors: Djalila Mekahli, Max C. Liebau, Melissa A. Cadnapaphornchai, Stuart L. Goldstein, Larry A. Greenbaum, Mieczyslaw Litwin, Tomas Seeman, Franz Schaefer, Lisa M. Guay-Woodford
Format: Article
Language:English
Published: BMC 2023-02-01
Series:BMC Nephrology
Subjects:
Autosomal recessive polycystic kidney disease (ARPKD)
Clinical trial
Tolvaptan
Pediatric
Efficacy
Safety
Online Access:https://doi.org/10.1186/s12882-023-03072-x

Internet

https://doi.org/10.1186/s12882-023-03072-x

Similar Items